Name | Gadoteridol |
Synonyms | gadotridol Gadoteridol ICG-Maleimide ICG-Hydrazide disulfo-ICG-NHS diSulfo-ICG Hydrazide diSulfo-ICG Maleimide triSulfo-Cy5.5 Maleimide triSulfo-Cy5.5 hydrazide gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate |
CAS | 120066-54-8 |
EINECS | 1533716-785-6 |
InChI | InChI=1/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3 |
Molecular Formula | C17H29GdN4O7 |
Molar Mass | 558.68 |
Melting Point | 188-193 °C |
Boling Point | 668.2°C at 760 mmHg |
Flash Point | 357.9°C |
Vapor Presure | 1.04E-20mmHg at 25°C |
Storage Condition | Room Temprature |
Risk Codes | R22 - Harmful if swallowed R25 - Toxic if swallowed R36 - Irritating to the eyes R50 - Very Toxic to aquatic organisms R43 - May cause sensitization by skin contact R41 - Risk of serious damage to eyes |
Safety Description | S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. S36/37 - Wear suitable protective clothing and gloves. S39 - Wear eye / face protection. |
HS Code | 2942000000 |
magnetic resonance imaging contrast agent | gadolinium injection is a patented magnetic resonance imaging (MRI) contrast agent developed by BRACCO S.P.A in Italy. it is a gadolinium-containing contrast agent, which is mainly used to enhance the image quality of internal organs, blood vessels and tissues during MRI examination. Various chelating agents of gadolinium that can be injected intravenously have become an indispensable part of magnetic resonance imaging (MRI) technology. The clinical safety application of gadolinium contrast agent Chinese expert recommendations (2019) pointed out that it is generally believed that gadolinium contrast agent is safe, and gadolinium terol is a large cyclic chelate with high stability and small adverse reactions. The clinical prospects of special alcohol are better. Listed in the UK in 1992 and listed in China in 2014, it has been approved and listed in 22 countries including Japan, the United States and the European Union. |
indication | 1) for magnetic resonance (MR) enhanced scanning of brain, spine and surrounding tissue lesions. 2) Used for whole body magnetic resonance examination, including examination of head, neck, liver, breast, musculoskeletal system and soft tissue diseases. |
Clinical evaluation | Gadolinide alcohol is similar to Gadolinamide in terms of additional diagnostic information scores and radiological effects of improving image contrast. In terms of safety, in the trial of brain and spinal MRI, 1 (1.7%) subjects in the gadolinium group had adverse events, and 4 (6.9%) subjects in the gd meglumine group had adverse events. In the liver, head and neck and breast MRI tests, 4 subjects (6.0%) in the gadolinium group and 6 subjects (8.6%) in the gd meglumine group had adverse events. All adverse events were mild or moderate. The main adverse reactions of this product are nausea, diarrhea, elevated ALT and elevated AST. It is suggested that subjects receiving gadolinium terol or gadolinium glucamine spray showed similar safety characteristics. The results of clinical trials at home and abroad show that in the central nervous system and systemic MRI examination, the application of enhanced magnetic resonance examination of this product can effectively improve the sensitivity and specificity of disease diagnosis; at the same time, this product has acceptable safety. |
Biological activity | Gadolinol is a gadolinium-containing MRI contrast agent used for central nervous system imaging and used as an MRI contrast agent. |
toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |